GOLGA6A Inhibitors
GOLGA6A inhibitors encompass a spectrum of compounds that exert their effects through various mechanisms, each converging on the disruption of Golgi apparatus functions where GOLGA6A operates. Brefeldin A, for instance, dismantles Golgi structure by inhibiting ARF, which is critical for vesicular transport processes that GOLGA6A is associated with. Similarly, Monensin and Golgicide A destabilize Golgi apparatus functioning by altering intracellular pH and inhibiting GBF1, respectively, both of which are crucial for GOLGA6A's role in vesicular tethering and fusion. Microtubule-targeting agents like Nocodazole and Colchicine indirectly affect GOLGA6A by obstructing the transport to and from the Golgi, while Dynasore specifically halts vesicle scission, thereby impeding GOLGA6A's involvement in membrane dynamics. Disruption of glycoprotein processing pathways, a function tied to GOLGA6A, is another strategy employed by inhibitors like Tunicamycin and Swainsonine, which block N-linked glycosylation and mannosidase II, respectively.
Furthermore, compounds such as Griseofulvin, which disrupt microtubule function, and IL-1 beta inhibitor, which lessens Golgi expansion during inflammatory responses, result in a downstream decrease of GOLGA6A activity due to compromised intracellular transport and Golgi architecture. Castanospermine's inhibition of glucosidase I and II enzymes leads to an accumulation of misfolded glycoproteins and subsequent Golgi dysfunction, thus indirectly diminishing GOLGA6A's glycoprotein processing capabilities. Lastly, Retro-2cycl, by blocking retrograde transport from endosomes to the Golgi, disrupts the delivery of key molecules and substrates that GOLGA6A would typically handle, reinforcing its role as an indirect inhibitor of GOLGA6A activity. Each of these inhibitors operates through distinct biochemical pathways but converges on the modulation of Golgi apparatus functionality, thereby influencing the role of GOLGA6A in cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus structure by inhibiting ADP-ribosylation factor (ARF), which is essential for the maintenance and formation of Golgi structure. As GOLGA6A is a Golgi apparatus protein, this compound indirectly leads to the functional inhibition of GOLGA6A by collapsing its structural integrity. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that disrupts Golgi function by altering the pH and preventing vesicular transport within Golgi stacks. Since GOLGA6A is localized to the Golgi apparatus, monensin's action results in the inhibition of GOLGA6A's functional role in vesicle tethering and fusion. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole disrupts microtubule polymerization, which affects transport to and from the Golgi apparatus. As GOLGA6A is involved in Golgi-microtubule interaction, nocodazole indirectly inhibits GOLGA6A by disrupting its associated transport mechanisms. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
Golgicide A is a selective inhibitor of the Golgi BFA resistance factor 1 (GBF1), a GEF for the ARF family of small GTPases. Since GOLGA6A requires proper Golgi apparatus function, inhibition of GBF1 by Golgicide A indirectly inhibits the functional activity of GOLGA6A. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, a process taking place in the Golgi. Therefore, the inhibition of this process can lead to improper protein folding and Golgi function, indirectly affecting GOLGA6A's role in glycoprotein transport. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore inhibits dynamin, a GTPase involved in vesicle scission from the Golgi. GOLGA6A, being associated with Golgi membrane dynamics, is indirectly inhibited in its function due to the blockade of vesicle release from the Golgi. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $98.00 $315.00 $2244.00 $4396.00 $17850.00 $34068.00 | 3 | |
Colchicine binds to tubulin, preventing its polymerization into microtubules, which are essential for Golgi function and positioning. The resulting microtubule disruption indirectly inhibits GOLGA6A function which is reliant on an intact Golgi structure. | ||||||
Griseofulvin | 126-07-8 | sc-202171A sc-202171 sc-202171B | 5 mg 25 mg 100 mg | $83.00 $216.00 $586.00 | 4 | |
Griseofulvin disrupts microtubule function by binding to tubulin. This action impairs intracellular transport to the Golgi apparatus, thus indirectly inhibiting the functional activity of GOLGA6A. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
Swainsonine inhibits mannosidase II, an enzyme in the Golgi responsible for processing glycoproteins. This inhibition affects glycoprotein trafficking and maturation, processes where GOLGA6A is implicated, and thus indirectly impedes GOLGA6A's functional role. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $180.00 $620.00 | 10 | |
Castanospermine inhibits glucosidase I and II, enzymes involved in the processing of N-linked glycopeptides in the Golgi. This leads to an accumulation of misfolded glycoproteins, thereby indirectly disrupting the function of GOLGA6A related to glycoprotein processing. | ||||||